BBR 2778 ( DrugBank: - )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 11 | Myasthenia gravis | 1 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 2 |
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-002817-37-IT (EUCTR) | 29/07/2008 | 30/06/2008 | A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS - ND | A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS - ND | Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis. MedDRA version: 9.1;Level: LLT;Classification code 10028417;Term: Myasthenia gravis | Product Name: PIXANTRONE Product Code: BBR 2778 INN or Proposed INN: pixantrone | ISTITUTO NEUROLOGICO CARLO BESTA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Italy |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-003086-40-BE (EUCTR) | 25/02/2009 | 21/11/2007 | A Phase I/II study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | A Phase I/II study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | Product Name: Pixantrone Product Code: BBR 2778 INN or Proposed INN: Pixantrone | Fondation Charcot Stichting | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 1;Phase 2 | Belgium;France | ||
| 2 | EUCTR2007-003086-40-FR (EUCTR) | 08/04/2008 | 13/11/2007 | A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | A Phase I/II Study of Pixantrone in Patients with an Aggressive Relapsing Remitting (RR) or Secondary Progressive (SP) Multiple Sclerosis (PIXAMS) | aggressive relapsing remitting (RR) or secondary progressive (SP) multiple sclerosis | Product Name: Pixantrone Product Code: BBR 2778 INN or Proposed INN: Pixantrone | Fondation Charcot Stichting | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 20 | Phase 1/2 | France |